SCHEMBL206209

SCHEMBL206209

CN(C)C(=O)c1ccc(Nc2nc(-c3cccnc3)cs2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.75
NPC1 O15118 10/20 0.75
MAPT P10636 6/20 0.71
SMN1; SMN2 Q16637 5/20 0.71
GAA P10253 3/20 0.71
MAPK1 P28482 2/20 0.71
TDP1 Q9NUW8 2/20 0.71
TP53 P04637 1/20 0.71
PKM P14618 2/20 0.69
VCP P55072 1/20 0.69
MEN1 O00255 13/20 0.65
KMT2A Q03164 13/20 0.65
LMNA P02545 1/20 0.65
CASP3 P42574 2/20 0.64
SENP8 Q96LD8 2/20 0.64
SENP7 Q9BQF6 2/20 0.64
SENP6 Q9GZR1 2/20 0.64
NCOA3 Q9Y6Q9 1/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206596 0.88 RAB9A (0.71) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL14155921 0.86 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL208199 0.86 RAB9A (0.82) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL12297416 0.83 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL206539 0.82 SMN1; SMN2 (0.77) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL3794417 0.82 NPC1 (0.71) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL1886996 0.82 VCP (1.00) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL206486 0.82 MEN1 (0.76) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL4579101 0.81 RAB9A (0.71) RAB9ANPC1MAPTSMN1; SMN2GAA
SCHEMBL12639823 0.80 MAPK1 (0.86) RAB9ANPC1MAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 RAB9A 1357/4885NPC1 62/4885MAPT 2207/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 RAB9A 1357/4885NPC1 62/4885MAPT 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.